Table 1 Baseline and follow-up characteristics of the study population

General characteristics

 Gender, n male (%)

*

7 (87.5)

15 (71.4)

14 (60.9)

0.36

 Western ethnicity, n (%)

*

8 (100.0)

21 (100.0)

19 (82.6)

0.13

 Ever injected drugs, n (%)

*

8 (100.0)

21 (100.0)

23 (100.0)

1.00

 Years of injecting (IQR)

*

6.7 (6.1–13.6)

13.4 (5.4–19.6)

9.0 (6.4–14.6)

0.20

Baseline (T = 1)

 Age, median (IQR)

36.4 (31.5–40.1)

32.8 (28.7–35.2)

34.4 (30.7–37.5)

35.2 (32.6–39.8)

0.30

 Sample since study entry

*

12.7 (0–47.6)

12.6 (1.7–31.7)

14.7 (0–25.8)

0.98

 (months), median (IQR)

 Year of sample,

*

1992 (1989–1994)

1992 (1990–1994)

1991 (1989–1993)

0.43

 median (IQR)

 Injecting past 6 months(%)

*

1 (12.5)

14 (66.7)

16 (73.9)

0.07

 CD 4 cell counts 10⁶ cells/L,

*

*

*

590 (470–742)

*

 median (IQR)

 cART, n (%)

*

*

*

1 (4.5)

*

Follow-up (T = 2)

 Age, median (IQR)

52.7 (48.3–57.6)

51.7 (49.2–54.8)

51.7 (47.4–55.5)

50.4 (47.7–54.2)

0.97

 Injecting past 6 months (%)

*

1 (12.5)

4 (19.0)

4 (17.9)

0.92

 CD 4 cell counts 10⁶ cells/L,

*

*

*

341 (233–663)

*

 median (IQR)

 cART, n (%)

*

*

*

20 (87.0)

*

 Years on cART, median (IQR)

*

*

*

7.1 (2.1–10.7)

*